Ausio header

 

mainphoto

Ausio Pharmaceuticals, LLC, is a clinical-stage biotechnology development company focused on the advancement of safe and effective medicines for the aging population. Ausio’s lead product is AUS-131, a first-in-class, nonsteroidal, nonhormonal estrogen receptor β (ERβ) agonist that offers a potentially safer alternative to estrogen for the treatment of menopausal symptoms. Ausio has successfully completed two Phase 1 trials and a Phase 2a for menopausal symptoms. AUS-131 is also being evaluated for its potential to treat benign prostatic hyperplasia (BPH) and other indications. The company has garnered a strong patent position for AUS-131.


Ausio has rapidly developed AUS-131 as a pharmaceutical agent through a rigorous drug development process, as required by the US Food and Drug Administration. Ausio’s strategic goal is to collaborate with partners for AUS-131 in the United States and other markets worldwide.

 

 

 

Home Contact UsDirections